Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Biomarker analysis to predict response in patients with metastatic mismatch repair proficient colorectal cancer treated with regorafenib and nivolumab.
Authors
Ruoyu Miao
H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;
Ruoyu Miao , Dae Won Kim , James Yu , Bence Kovari , Rutika Mehta , Jonathan R. Strosberg , Iman Imanirad , Seema Iyer , Mark Uhlik , Laura E. Benjamin , Richard D. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 228)
DOI
10.1200/JCO.2023.41.4_suppl.228
Abstract #
228
Poster Bd #
M10
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Results from a phase 1a/1b study of botensilimab (BOT), a novel innate/adaptive immune activator, plus balstilimab (BAL; anti-PD-1 antibody) in metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC).
First Author: Anthony B. El-Khoueiry
Poster
2022 ASCO Annual Meeting
Dysfunctional CD8+ T cells in the tumor microenvironment are associated with response to nivolumab in mismatch repair deficient (dMMR) or hypermutated ovarian (OVCA) or endometrial cancer (EC).
First Author: Claire Frances Friedman
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Impact of time-of-day on nivolumab monotherapy infusion in patients with metastatic gastric cancer.
First Author: Yasunobu Ishizuka
Poster
2023 ASCO Annual Meeting
A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer.
First Author: Julie L. Koenig